JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target

Benzinga · 1d ago
JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and announces $40 price target.